TOP > 外国特許検索 > CELL MIGRATION MODULATOR

CELL MIGRATION MODULATOR

外国特許コード F130007171
整理番号 S2012-0845-N0
掲載日 2013年2月25日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP079263
国際公開番号 WO 2012081711
国際出願日 平成23年12月12日(2011.12.12)
国際公開日 平成24年6月21日(2012.6.21)
優先権データ
  • 特願2010-276777 (2010.12.13) JP
発明の名称 (英語) CELL MIGRATION MODULATOR
発明の概要(英語) Provided are: a cell migration modulator, a cell migration modulation method, a medical composition containing the modulator, and the like, which make possible the promotion and suppression of cell migration. This cell migration modulator is characterized in comprising the entire length of blood coagulation factor IX, a portion where the trypsin domain has been removed from the entire length of blood coagulation factor IX, a light chain of blood coagulation factor IX, or a peptide, derivative thereof, or salt thereof, the peptide including the EGF1 domain of blood coagulation factor IX or the EGF3 domain of endothelial cell locus-1 protein.
従来技術、競合技術の概要(英語) BACKGROUND ART
9 Hemostatic clotting factors that are involved in the coagulation of the long-known (F9) is an essential and blood coagulation factors, protein known as the cause of hemophilia. F9 Is, in the course of the coagulation reaction (F11) coagulation factor 11 by the two fragments of the 2 (heavy chain, light chain) or the like can be cleaved by activated, to promote the coagulation reaction. F9 In, coagulation factor has a function as a critical part is the C-terminal side of the trypsin domain (heavy chain) and, the function of the N-terminal side (light chain) is not well known. Thrombus caused by blood coagulation, comprising a coagulation factor composed of a variety of proteins. Up to now, is easily formed within the thrombus or blood vessels, thrombus formation rate found in cancer patients confirmed that cancer metastasis is high (for example, non-patent document 1;Gerotziafas GT et al., see Thromb.,2008,vol.36(3-4), p.204-11 Clinical studies with anticoagulants to improve survival in cancer patients.Pathophysiol Haemost.), The mechanism and the main molecule has still not constant inconclusive. The relationship between the cancer metastasis and the thrombus was demonstrated by statistically, cancer metastasis by administering an anticoagulant to prevent the been made an attempt, a significant inhibition of cancer metastasis was confirmed. However, the use of anti-coagulant because it involves the risk of bleeding, there is a limit to the amount used. In addition, experience has shown that the methods are effective, mechanism is unknown, and widely have not yet been accomplished. However, cell migration, phenomenon which is essential in the life activities of the human body, human body involved in a wide range of phenomenon occurs but, at the same time, metastasis may cause undesirable results are known. In addition, other receptors involved in cell migration phenomenon may be, or angiogenesis, wound healing and the like are known.
In such a situation, enhancement or inhibition of cell migration can be performed with a cell migration-modulating agents, a method of controlling cell migration, and a pharmaceutical composition comprising the modulating agent has been desired development of. The present invention is, in consideration of the above circumstances with an object, shown below, cell migration modulating agent (for example, cell migration promoting agents, cell migration inhibitor), a method of controlling cell migration (for example, promoting cell migration, cell migration inhibition method), a pharmaceutical composition comprising the modifier (angiogenesis-promoting, wound or ulcer for, a cancer metastasis suppressing or inhibitory, or angiogenesis inhibitor or a pharmaceutical composition for the inhibition), as well as, for promoting the expansion of the cells, epithelial-like sequence of the cell holding method, developed The composition of cells, and cells of epithelial-like sequence composition and the like for holding system according to the invention. (1) 9 The entire length of the blood clotting factors, blood clotting factors of the total length of the portion except for the 9 trypsin domain, light chain 9 of the blood clotting factors, blood clotting factors 9 or EGF1 domain, EGF3 domain of the protein or endothelial cells a peptide containing the -1 locus, its derivatives or salts thereof and, cell migration-modulating agents. (2) (A) or (b) the following peptide, its derivatives or salts thereof and, cell migration-modulating agents. (a) Shown in SEQ ID NO:2, 4, 6, 8 or 12 comprising an amino acid sequence. (b) Amino acid sequence shown in SEQ ID NO:2, 4, 6, 8 or 12 in 1 or an amino acid deletion, substitution or addition of the amino acid sequence, and, a peptide having the cell migration activity. (3) (A) or (b) the following peptide, its derivatives or salts thereof and, cell migration promoting agent. (a) SEQ ID NO:6, or 8 comprising an amino acid sequence shown in 12. (b) SEQ ID NO:6, 1 or 8 the amino acid sequence shown in 12 or an amino acid deletion, substitution or addition of the amino acid sequence, and, a peptide having the activity to promote cell migration. (4) (A) or (b) the following peptide, its derivatives or salts thereof characterized in that, the cell migration inhibitor. (a) SEQ ID NO:2, 4, 8 or comprising an amino acid sequence shown in 12. (b) Amino acid sequence shown in SEQ ID NO:2, 4, 8 or 12 in 1 or an amino acid deletion, substitution or addition of the amino acid sequence, and, a peptide having cell migration inhibitory activity. (5) Animals of claims 1 or 2 and adjusted to be administered, method for the regulation of cell migration. (6) Promoter according to claim 3 animals and administering, promoting cell migration. (7) Inhibitor according to claim 4 animals characterized by administering, method of inhibiting cell migration. (8) Modifier of claims 1 or 2, the pharmaceutical composition. (9) Of an accelerator according to claim 3, pro-angiogenic pharmaceutical composition. (10) Of an accelerator according to claim 3, a pharmaceutical composition for wound or ulcer. (11) An inhibitor of according to claim 4, a pharmaceutical composition for inhibiting or blocking cancer metastasis. (12) An inhibitor of according to claim 4, a pharmaceutical composition for inhibiting or blocking angiogenesis. (13) Of the accelerating agents according to claim 3 characterized in that, for promoting the expansion of the cells. (14) According to claim 4 and inhibitors of, epithelial-like sequence of the cell holding method. And (14) in the methods of the above (13), cells include, for example and the cultured cells. (15) Of an accelerator according to claim 3, deployment of cells The composition. (16) Of an inhibitor according to claim 4, epithelial-like sequence composition for holding cells. And (16) in the compositions of the above (15), cells include, for example and the cultured cells. According to the present invention, enhancement or inhibition of cell migration cell migration-modulating agents can be performed, for example, to stimulate or inhibit the cell migration agent can be provided. Of the present invention cell migration-modulating agents include, for example, promoting angiogenesis, wound or ulcer treatment, inhibits or prevents cancer metastasis, or inhibit angiogenesis or inhibit be used in a pharmaceutical composition, and medical and pharmaceutical field of, is extremely useful. In addition, cell migration-modulating agents are of the present invention, by the promotion of cell migration to facilitate spreading of the cells (particularly the cells in culture) or, by the inhibition of cell migration of epithelial cells (particularly the cells in culture) of a target-like sequence may be used to hold is also effective.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIHON UNIVERSITY
  • 発明者(英語)
  • HIDAI, Chiaki
  • KITANO, Hisataka
  • MAMIYA, Atsushi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
日本大学産官学連携知財センター(通称NUBIC,ニュービック)は,技術移転機関と知的財産本部の機能を兼ね備えた日本大学の産学連携の窓口です。
NUBICは,日本大学全教職員や大学院生・学部学生の豊富なアイデアや研究成果を,知的財産として戦略的に創出・保護・管理し,産業界のニーズとのマッチングを図り,企業の研究開発,新製品開発,新規事業の立上げが円滑に行われるようサポートいたします。
お気軽にご相談ください。

PAGE TOP

close
close
close
close
close
close